Continuous infusion of remimazolam for intraoperative sedation as a safe and effective option: a prospective clinical study.

Drug: remimazolam For patients undergoing elective procedural sedation or sedation with regional anaesthesia. Anticipated duration of the procedure is up to one hour. Bispectral Index (BIS) monitoring using sensors which are placed on the forehead of participants is used to measure the participant's level of consciousness and with that to monitor the depth of anaesthesia. The examiner will use Modified Observer's Alertness/Sedation scale (MOAA/S) and Richmond Agitation-Sedation Scale (RASS) values to measure the agitation or sedation level of a participants. The examiner will measure MOAA/S and RASS values at the beginning of the procedure. Remimazolam will be started with the loading dose of 5mg intravenously over a 1-minute time period. After the loading dose, the continuous intravenous infusion of remimazolam will start, which will be titrated to maintain the target Bispectral Index (BIS) values of 60-80 during procedure, which indicates an adequate depth of sedation. During the entire procedure, BIS, MOAA/S and RASS values will be measured and recorded at 5-minute intervals, and depending on the obtained values, the remimazolam infusion rate will be corrected. At the end of the procedure, after stopping the administration of the drug, the time required from the end of the infusion to the complete recovery of consciousness will be measured.